Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith A Aberg

Showing results (161-170 of 212) with videos related to

Pageof 22
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2023
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE CohortBorek Foldyna, Thomas Mayrhofer, Markella V Zanni, et al.
JCI Insight|February 22, 2023
Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIVSamuel R Schnittman, Wonyeong Jung, Kathleen V Fitch, et al.
Frontiers in Immunology|March 27, 2023
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiativeHector Bonilla, Michael J Peluso, Kathleen Rodgers, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
AIDS (London, England)|July 25, 2022
Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskKathleen V Fitch, Sara A McCallum, Kristine M Erlandson, et al.
The Lancet. HIV|June 7, 2025
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J Fichtenbaum, Carlos D Malvestutto, Maya G Watanabe, et al.
Circulation. Heart Failure|December 29, 2025
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S Bloomfield, Maya Watanabe, Sara McCallum, et al.
The Lancet. HIV|January 20, 2025
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven K Grinspoon, Markella V Zanni, Virginia A Triant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical FunctionKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2022
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic RiskKristine M Erlandson, Kathleen V Fitch, Sara A McCallum, et al.
Pageof 22

Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2023
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE CohortBorek Foldyna, Thomas Mayrhofer, Markella V Zanni, et al.
JCI Insight|February 22, 2023
Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIVSamuel R Schnittman, Wonyeong Jung, Kathleen V Fitch, et al.
Frontiers in Immunology|March 27, 2023
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiativeHector Bonilla, Michael J Peluso, Kathleen Rodgers, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
AIDS (London, England)|July 25, 2022
Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskKathleen V Fitch, Sara A McCallum, Kristine M Erlandson, et al.
The Lancet. HIV|June 7, 2025
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J Fichtenbaum, Carlos D Malvestutto, Maya G Watanabe, et al.
Circulation. Heart Failure|December 29, 2025
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S Bloomfield, Maya Watanabe, Sara McCallum, et al.
The Lancet. HIV|January 20, 2025
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven K Grinspoon, Markella V Zanni, Virginia A Triant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical FunctionKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2022
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic RiskKristine M Erlandson, Kathleen V Fitch, Sara A McCallum, et al.
Pageof 22